Answers are grounded in this paper and cite their sources.
Aim: This study aimed to compare the prognostic outcomes of cytokeratin (CK) 19-positive and CK19-negative hepatocellular carcinoma (HCC), focusing on clinicopathological features and the impact of targeted therapy in CK19-positive patients. Methods: A retrospective analysis was performed on 310 HCC patients who underwent curative resection between 2010 and 2020 at the First Affiliated Hospital of Nanjing Medical University. Among them, 168 were CK19-positive and 102 were CK19-negative. Multivariate Cox regression was used to identify independent predictors of overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier survival curves were generated from the Cox model. Results: CK19-positive patients exhibited significantly poorer tumor differentiation (P < 0.001), increased microvascular invasion (P = 0.010), elevated α-fetoprotein (AFP) (P = 0.0001) and were more often asymptomatic at diagnosis (P = 0.014). The median survival time (MST) was 22.1 months in CK19-positive versus 60.3 months in CK19-negative patients. Among those with recurrence, MST was 56.4 months for CK19-positive and 101.6 months for CK19-negative patients. CK19 status significantly impacted OS (P < 0.001) and RFS (P = 0.006) in advanced-stage cases. Independent prognostic factors for RFS included cirrhosis, tumor size, number of tumors, macrovascular invasion, poor differentiation, and CK19 expression. Microvascular invasion and Child-Pugh classification were additional predictors of OS. Targeted therapies did not significantly improve outcomes in CK19-positive patients. Conclusions: CK19-positive HCC is associated with more aggressive tumor behavior, higher recurrence, and poorer survival. Targeted therapy provided no significant survival benefit in this study.
No takes yet. Share an insight, caveat, or question.
Khodabocus et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: